Upcoming Issue Highlights
Home Subscribe Advertise Sourcebook Free Product Info Home

Cyrex Laboratories Launches Array 3

Cyrex

Cyrex Laboratories (Phoenix, AZ), a clinical laboratory specializing in functional immunology and autoimmunity, has launched its Array 3 Wheat/Gluten Proteome Reactivity and Autoimmunity test panel to provide health care professionals with accurate results in identifying their patients’ gluten reactivity and related autoimmunity.

Cyrex Array 3 is the only wheat/gluten panel that assesses three antigen triggers of disorders (gluten proteins, opioid peptides and tissue binding isolates), and was developed to differentiate between the celiac manifestation and the non-celiac gluten sensitivity.

“Based on articles published in scientific journals, an astounding 50 percent of patients diagnosed with celiac disease receive a false negative test result when measuring only deamidated alpha gliadin-33-mer antibody,” said Dr. Aristo Vojdani, pioneer of ELISA food reactivity testing and chief scientific advisor for Cyrex Laboratories. “This is problematic because these gluten-reactive patients, who do not respond to alpha-gliadin-33-mer, instead may react to one or more of the other gluten proteins that are not being measured by other testing panels. This problem is exactly why Array 3 was developed.”

Cyrex Array 3 is unique because it accurately identifies gluten reactivity and measures antibody production against eight wheat proteins and peptides, three essential enzymes (transglutaminase-2, transglutaminase-3 and transglutaminase-6), and the gliadin transglutaminase complex.

Array 3 is recommended for patients who have non-responsive GI (gastrointestinal) symptoms, present with multiple-symptom complaints (including joint pain, fatigue, muscle pain, brain fog, hormone imbalances and chronic inflammation), and suffer from depression or neurodegenerative symptoms like peripheral neuropathy, Alzheimer’s disease or multiple sclerosis.

“The Cyrex Array 3 offers the most comprehensive analysis available for determining gluten sensitivity,” said David Perlmutter, MD, FACN, and author of the New York Times’ Best Seller Grain Brain. “This array has proven incredibly valuable in my practice by providing in-depth information about an issue that has wide clinical implications.”

For more information, visit www.joincyrex.com.